Comparison of mesenchymal stromal cells from human bone marrow and adipose tissue for the treatment of spinal cord injury.
Zhou Z., Chen Y., Zhang H., Min S., Yu B., He B.
Prospective Study on Spinal Cord Injury, published in Cytotherapy (2013) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Cytotherapy (2013)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 23376106
- DOI
- 10.1016/j.jcyt.2012.11.015
Abstract (original English)
Bone marrow and subcutaneous adipose tissue are both considered prospective sources of mesenchymal stromal cells (MSCs), which can be used in cell therapy for spinal cord injury (SCI). The present study investigated whether human adipose tissue-derived mesenchymal stromal cells (hADSCs) transplanted into a rat model of SCI would lead to similar or improved neurologic effects compared with human bone marrow-derived mesenchymal stromal cells (hBMSCs). hADSCs and hBMSCs were isolated from five adult donors. These MSCs were characterized using flow cytometry, immunocytochemistry, real-time polymerase chain reaction and enzyme-linked immunosorbent assay. Immediately after SCI, 2 × 10(5) hBMSCs or hADSCs were injected into the injured spinal cord. Locomotor function, cell survival and differentiation, spinal cord tissue morphology and brain-derived neurotrophic factor (BDNF) expression were compared between groups. hADSCs and hBMSCs showed similar surface protein expression, and hADSCs showed higher proliferative activity with higher expression of vascular endothelial cell growth factor, hepatocyte growth factor and BDNF than hBMSCs. After transplant, both hADSCs and hBMSCs migrated within the injured spinal cord without differentiating into glial or neuronal elements. Administration of hADSCs was associated with marked changes in the SCI environment, with significant increases in BD
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Host immune determinants of stromal vascular fraction graft survival: Toward a concept of SVF therapy resistance - A systematic narrative review.
Systematic Review on Spinal Cord Injury, Chronic Inflammation, Immune Modulation, published in Cell Transplant (2026) — summary generated from the PubMed abstract.
- 2026
Cell Transplant - Level AMeta-analysisPubMed
Stem cell-derived exosome treatment for acute spinal cord injury: a systematic review and meta-analysis based on preclinical evidence.
Meta-analysis on Spinal Cord Injury, published in Front Neurol (2025) — summary generated from the PubMed abstract.
- 2025
Front Neurol - Level ASystematic ReviewPubMed
Brain-derived neurotrophic factor (BDNF) as biomarker in stem cell-based therapies of preclinical spinal cord injury models: A systematic review.
Systematic Review on Spinal Cord Injury, published in Tissue Cell (2025) — summary generated from the PubMed abstract.
- 2025
Tissue Cell3 citations - Level ASystematic ReviewEurope PMC
Revolutionizing neural regeneration with smart responsive materials: Current insights and future prospects
Systematic Review on Spinal Cord Injury, published in Bioact Mater (2025) — summary generated from the PubMed abstract.
- 2025
Bioact Mater5 citations - Level ASystematic ReviewEurope PMC
Conductive Nanocomposite Hydrogels for Neural Tissue Engineering: A Systematic Scoping Review of Recent Trends
Systematic Review with a reported sample of 42 on Diabetic Foot, Stroke Research, Spinal Cord Injury, Neuroinflammation, published in Adv Sci (Weinh) (2025) — summary generated from the PubMed abstract.
- 2025
- n = 42
Adv Sci (Weinh)18 citations - Level ASystematic ReviewEurope PMC
Emerging regenerative strategies for spinal cord injury: exosome-derived mechanisms and therapeutic insights
Systematic Review on Spinal Cord Injury, Neuroinflammation, published in Front Neurosci (2025) — summary generated from the PubMed abstract.
- 2025
Front Neurosci